Key result
Intermountain Risk Score poorly predicts 90-day postdischarge HA-VTE and is inferior to existing risk models.
Why the study?
Discharged medical patients are at risk for VTE, but identifying those who benefit from extended thromboprophylaxis is difficult. This study evaluated whether the Intermountain Risk Score predicts 90-day postdischarge hospital-associated VTE.
Does the Intermountain Risk Score accurately predict 90-day postdischarge hospital-associated VTE in medical patients compared to existing risk assessment models?
Cohort (n=60,064)
Does the Intermountain Risk Score accurately predict 90-day postdischarge hospital-associated VTE in medical patients compared to existing risk assessment models?
Effect estimate: AUC 0.58 (95% CI 0.56-0.60)
p-value: p=< .001
The Intermountain Risk Score is a poor predictor of postdischarge hospital-associated VTE and does not improve upon existing risk assessment models.
May aid postdischarge VTE risk stratification; hypothesis-generating and requires prospective validation before practice change.
Background Discharged medical patients are at risk for venous thromboembolism (VTE). It is difficult to identify which discharged patients would benefit from extended duration thromboprophylaxis. The Intermountain Risk Score is a prediction score derived from discrete components of the complete blood cell count and basic metabolic panel and is highly predictive of 1-year mortality. We sought to ascertain if the Intermountain Risk Score might also be predictive of 90-day postdischarge hospital-associated VTE (HA-VTE). Methods We applied the Intermountain Risk Score to 60 064 medical patients who survived 90 days after discharge and report predictiveness for HA-VTE. Area under the receiver operating curve analyses were performed. We then assessed whether the Intermountain Risk Score improved prediction of 2 existing VTE risk assessment models. Results The Intermountain Risk Score poorly predicted HA-VTE (area under the curve = 0.58; 95% confidence interval [CI], 0.56-0.60). Each clinical risk assessment model was superior to the Intermountain Risk Score (UTAH area under the curve, 0.63; Kucher area under the curve, 0.62; Intermountain Risk Score area under the curve, 0.58; P < .001 for each comparison). Adding the Intermountain Risk Score to these scores did not substantially improve the performance of either risk assessment model (UTAH + Intermountain Risk Score, 0.65; Kucher + Intermountain Risk Score, 0.64). Conclusion The Intermountain Risk Score demonstrated poor predictiveness for HA-VTE when compared to existing risk assessment models. Adding the Intermountain Risk Score to existing risk assessment models did not improve upon either risk assessment model alone to justify the added complexity.
No takes yet. Share an insight, caveat, or question.
Snyder et al. (2020) conducted a cohort in Risk for venous thromboembolism (VTE) (n=60,064). Intermountain Risk Score vs. UTAH and Kucher risk assessment models was evaluated on 90-day postdischarge hospital-associated VTE (HA-VTE) prediction (AUC 0.58, 95% CI 0.56-0.60, p=< .001). The Intermountain Risk Score poorly predicted 90-day postdischarge hospital-associated VTE (AUC 0.58; 95% CI 0.56-0.60) and was inferior to existing clinical risk assessment models (P<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: